Cerebral Infarction
Conditions
Keywords
Cerebral infarction, Prevention, Cilostazol, Aspirin, Stroke, Clinical trial
Brief summary
The study design is subject to relevant SFDA regulations about clinical trials. This indication was approved in Japan in 2003. From the end of May 2004 to the end of Dec. 2004, 720 patients with previous cerebral infarction(see the inclusion criteria) were enrolled in to the study and received one of the two treatment regimens, Cilostazol or Aspirin, the ratio of patient number of each group is 1:1. For each patient, the chance of entering either of these two groups is the same. The treatment will continue till the end of 2005. During the treatment period, patients will be observed concerning some certain events, mainly reoccurrence of stroke. If the patient experiences reoccurrence of stroke, or other event that the doctors think it is not appropriate to continue the study medication, this patient would stop the treatment. Patients were also required to take MRI head scan before entering the study and on completion of the treatment.
Interventions
DRUGCilostazol 200mg/day Oral
DRUGAspirin 100mg/day Oral
Sponsors
Zhejiang Otsuka Pharmaceutical Co., Ltd.
Otsuka Beijing Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1\. Patients who had cerebral infarction within 6 months and 1 month before entry 2. Within a few days of the onset of cerebral infarction onset, CT or MRI showed evidence of infarction that could be responsible for this stroke onset 3. A modified ranking scale of less than 4 4. Aged 18\ 75 5. Consent of the patients or their legal guardians \-
Exclusion criteria
1\. History of intracranial hemorrhage 2. Stroke secondary to cardiogenic embolism 3. Serious damage of motorial function, dementia 4. Serious complications or co morbidity(uncontrolled accelerated type of hypertension, BP\>180/120mmHg, diabetic acidosis, heart failure, renal failure, hepatocirrhosis, malignant tumor) 5. Contraindication of Cilostazol and Aspirin 6. Patients who need co medication of other antiplatelet agents, anticoagulants or fibrinolytic drugs 7. Active peptic ulcer 8. Pregnancy or breast feeding 9. Judged to be inappropriate to enter the study by investigators. - \-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence of stroke(cerebral infarction/haemorrhage/subarachnoid haemorrhage) | — |
Secondary
| Measure | Time frame |
|---|---|
| Death due to cerebral vascular events | — |
| Myocardial infarction | — |
| Recurrence of cerebral infarction detected in MRI | — |
| TIA | — |
| Death | — |
| Vascular events(acute artery thrombosis/embolism, pneumonia embolism, venous thrombosis, angina pectoris) | — |
Countries
China
Outcome results
None listed